Active
Spikevax
Moderna's original COVID-19 mRNA vaccine (mRNA-1273), the product that validated mRNA vaccines at global scale. Now sold as a seasonal respiratory vaccine and the company's largest historical revenue driver.
ModernamRNA-4194 (INTERCEPT-Lynch)
In Development
An investigational mRNA cancer-prevention vaccine, developed with the University of Oxford, designed to generate immune responses against early cancer-development targets in people with Lynch syndrome - Moderna's first program aimed at preventing cancer before it develops rather than treating existing disease.
Latest update Aug 15, 2026
01
Current status
Phase 1/2 (INTERCEPT-Lynch), UK MHRA-authorized June 8, 2026; dosing began in the roughly 110-patient study, confirmed in Moderna's Q2 2026 earnings update. A larger Phase 2 expansion across multiple UK centers is expected to begin in 2027.
02
Specifications2
03
Upcoming milestones1
Announced next steps from Moderna that mention mRNA-4194 (INTERCEPT-Lynch).
2027
Begin Phase 2 expansion of mRNA-4194 Lynch syndrome trial
Expand the Phase 1/2 INTERCEPT-Lynch study of mRNA-4194, Moderna's cancer-prevention vaccine for people with Lynch syndrome, into a larger Phase 2 across multiple UK centers - the next step after Phase 1 dosing began in 2026 under the UK MHRA's June 8, 2026 authorization. Moderna's public pipeline still lists the program in Phase 1 as of the May 28, 2026 pipeline cut; no later start date for the Phase 2 expansion has been announced.
04
More from Moderna6
- Active
mRESVIA
mRNA vaccine (mRNA-1345) against respiratory syncytial virus (RSV) - the first mRNA vaccine approved for a disease other than COVID-19, and a key pillar of Moderna's expanding respiratory franchise.
- Active
mFlusiva
Moderna's standalone mRNA seasonal influenza vaccine (mRNA-1010), the fourth product in its respiratory franchise alongside Spikevax, mRESVIA, and mCOMBRIAX.
- In Development
Intismeran autogene (mRNA-4157)
An individualized neoantigen cancer therapy, co-developed with Merck, that is custom-manufactured for each patient's tumor mutations and given with KEYTRUDA to train the immune system against the cancer. It is Moderna's highest-value pipeline asset.
- Active
mCOMBRIAX
Moderna's combination COVID-19 and influenza vaccine (mRNA-1083), the world's first authorized flu-plus-COVID combination vaccine, delivered as a single shot.
- In Development
mRNA-1469
Investigational mRNA vaccine candidate against Bundibugyo ebolavirus. On Nov. 4, 2026 Moderna said WHO's Technical Advisory Group on Candidate Vaccine Prioritization recommended it for the Phase 2/3 Tumaini study in the Democratic Republic of the Congo after an Oct. 22 review. The study uses a ring-vaccination design and is co-sponsored by the Institut National de Recherche Biomedicale and the University of Antwerp. There is no licensed vaccine specifically indicated for Bundibugyo virus disease.
05
More in Biotech
In DevelopmentAurora Powerhouse
Oklo
Oklo's fast-fission powerhouse product line is designed for build-own-operate deployment, targeting customers that want firm clean power in a smaller footprint than traditional large reactors.
In DevelopmentFuel Recycling
Oklo
Oklo is developing an advanced fuel center to recycle used nuclear fuel and fabricate metal fuel for Aurora and other fast-reactor applications.
Early CommercializationAtomic Alchemy Isotope Platform
Oklo
Oklo's isotope business combines the Idaho Radiochemistry Laboratory, a planned pilot reactor in Texas, and a future multi-reactor foundry to supply critical medical, industrial, research, defense, and space isotopes.
In DevelopmentNatrium
TerraPower
Sodium-cooled fast reactor with integrated molten salt energy storage, enabling flexible output from 345 MWe to 500 MWe peak.